Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Equity Income (2021 - 2023)

Intellia Therapeutics (NTLA) has disclosed Equity Income for 3 consecutive years, with -$4.7 million as the latest value for Q4 2023.

  • On a quarterly basis, Equity Income fell 45.57% to -$4.7 million in Q4 2023 year-over-year; TTM through Sep 2024 was -$4.7 million, a 66.59% increase, with the full-year FY2023 number at -$15.6 million, down 41.1% from a year prior.
  • Equity Income was -$4.7 million for Q4 2023 at Intellia Therapeutics, down from -$3.9 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$1.3 million in Q4 2021 to a low of -$4.7 million in Q4 2023.
  • A 3-year average of -$3.1 million and a median of -$3.2 million in 2022 define the central range for Equity Income.
  • Peak YoY movement for Equity Income: plummeted 145.13% in 2022, then dropped 11.04% in 2023.
  • Intellia Therapeutics' Equity Income stood at -$1.3 million in 2021, then tumbled by 145.13% to -$3.2 million in 2022, then tumbled by 45.57% to -$4.7 million in 2023.
  • Per Business Quant, the three most recent readings for NTLA's Equity Income are -$4.7 million (Q4 2023), -$3.9 million (Q3 2023), and -$4.0 million (Q2 2023).